---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-018802"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:27:55.760072+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA approves Libervant for seizure clusters in children 2-5; Anaphylm NDA on track for end of 2024

## Summary
- Libervant is first FDA-approved oral rescue treatment for seizure clusters in patients ages 2-5.
- Immediate availability of 5mg, 7.5mg, 10mg, 12.5mg, and 15mg; non-Medicaid prescriptions being filled.
- Over 55,000 prescriptions filled in 2023 for this age group, 90% for diazepam rectal gel.
- Anaphylm clinical program on track; NDA submission planned by end of 2024.
- This is the Company's 4th FDA approval since 2018.

## SEC filing metadata
- accession: 0001628280-24-018802
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024018802/0001628280-24-018802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024018802/aqst-20240426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-018802
- JSON: https://secwatch.observer/filing/0001628280-24-018802.json
- Plain text: https://secwatch.observer/filing/0001628280-24-018802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.